Company intelligence / Profile preview

Pharmaclon

Ownership: Private
Development stage: Other

Overview

Pharmaclon is a Russian biotech/pharma company with multiple approved biosimilar and recombinant protein therapeutics targeting immune system diseases, neoplasms, infectious diseases, and more. Its portfolio includes biosimilars for interferon alfa‑2b and gamma as well as recombinant TNF modulators. Several products are approved in Russia for indications such as multiple sclerosis, acute lymphoblastic leukemia, warts, chlamydia infections, and neoplasms. No detailed clinical results are publicly available.

Therapeutic areas: DermatologyNeurologyOncologyInfectious Diseases
Modalities: Recombinant proteinBiosimilarSmall molecule
Industry: Biotech

Drug pipeline

4 assets

recombinant tumor necrosis factor alpha-thymosin alpha 1 fusion protein

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Pharmaclon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmaclon.

Explore the full profile